1Lehman CD. Role of MRI in screening women at high risk for breast cancer. J Magn Reson Imaging 2006; 24: 964-70.
2Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-76.
3D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA, et al. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology 2013: 56-71.
4Edwards SD, Lipson JA, Ikeda DM, Lee JM. Updates and revisions to the BI-RADS magnetic resonance imaging lexicon. Magn Reson Imaging Clin N Am 2013; 21: 483-93.
5Baltzer PA, Benndorf M, Dietzel M, Gajda M, Runnebaum IB, Kaiser WA. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study. AJR Am J Roentgenol 2010; 194: 1658-63.
6Torous VF, Resteghini NA, Phillips J, Dialani V, Slanetz PJ, Schnitt SJ, et al. Histopathologic correlates of nonmass enhancement detected by breast magnetic resonance imaging. Arch Pathol Lab Med 2021; 145: 1264-9.
7Shao Z, Wang H, Li X, Liu P, Zhang S, Cao S. Morphological distribution and internal enhancement architecture of contrast-enhanced magnetic resonance imaging in the diagnosis of non-mass-like breast lesions: a meta-analysis. Breast J 2013; 19: 259-68.
8Tozaki M, Igarashi T, Fukuda K. Breast MRI using the VIBE sequence: clustered ring enhancement in the differential diagnosis of lesions showing non-masslike enhancement. AJR Am J Roentgenol 2006; 187: 313-21.
9Uematsu T, Kasami M. High-spatial-resolution 3-T breast MRI of nonmasslike enhancement lesions: an analysis of their features as significant predictors of malignancy. AJR Am J Roentgenol 2012; 198: 1223-30.
10Morakkabati-Spitz N, Leutner C, Schild H, Traeber F, Kuhl C. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005; 15: 2010-7.
11Yang QX, Ji X, Feng LL, Zheng L, Zhou XQ, Wu Q, et al. Significant MRI indicators of malignancy for breast non-mass enhancement. J Xray Sci Technol 2017; 25: 1033-44.
12Yuen S, Uematsu T, Masako K, Uchida Y, Nishimura T. Segmental enhancement on breast MR images: differential diagnosis and diagnostic strategy. Eur Radiol 2008; 18: 2067-75.
13Ballesio L, Di Pastena F, Gigli S, D’ambrosio I, Aceti A, Pontico M, et al. Non mass-like enhancement categories detected by breast MRI and histological findings. Eur Rev Med Pharmacol Sci 2014; 18: 910-7.
14Machida Y, Tozaki M, Shimauchi A, Yoshida T. Two distinct types of linear distribution in nonmass enhancement at breast MR imaging: difference in positive predictive value between linear and branching patterns. Radiology 2015; 276: 686-94.
15Chen ST, Covelli J, Okamoto S, Daniel BL, DeMartini WB, Ikeda DM. Clumped vs non-clumped internal enhancement patterns in linear non-mass enhancement on breast MRI. Br J Radiol 2021; 94: 20201166.
16Gutierrez RL, DeMartini WB, Eby PR, Kurland BF, Peacock S, Lehman CD. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement. AJR Am J Roentgenol 2009; 193: 994-1000.
17Sakamoto N, Tozaki M, Higa K, Tsunoda Y, Ogawa T, Abe S, et al. Categorization of non-mass-like breast lesions detected by MRI. Breast Cancer 2008; 15: 241-6.
18Mahoney MC, Gatsonis C, Hanna L, DeMartini WB, Lehman C. Positive predictive value of BI-RADS MR imaging. Radiology 2012; 264: 51-8.
19Gity M, Ghazi Moghadam K, Jalali AH, Shakiba M. Association of different MRI BIRADS descriptors with malignancy in non mass-like breast lesions. Iran Red Crescent Med J 2014; 16: e26040.
20Asada T, Yamada T, Kanemaki Y, Fujiwara K, Okamoto S, Nakajima Y. Grading system to categorize breast MRI using BI-RADS 5th edition: a statistical study of non-mass enhancement descriptors in terms of probability of malignancy. Jpn J Radiol 2018; 36: 200-8.
21Aydin H. The MRI characteristics of non-mass enhancement lesions of the breast: associations with malignancy. Br J Radiol 2019; 92: 20180464.
22Chikarmane SA, Michaels AY, Giess CS. Revisiting nonmass enhancement in breast MRI: analysis of outcomes and follow-up using the updated BI-RADS Atlas. AJR Am J Roentgenol 2017; 209: 1178-84.
23Shimauchi A, Ota H, Machida Y, Yoshida T, Satani N, Mori N, et al. Morphology evaluation of nonmass enhancement on breast MRI: effect of a three-step interpretation model for readers’ performances and biopsy recommendations. Eur J Radiol 2016; 85: 480-8.
24Panigrahi B, Harvey SC, Mullen LA, Falomo E, Di Carlo P, Lee B, et al. Characteristics and outcomes of BI-RADS 3 lesions on breast MRI. Clin Breast Cancer 2019; 19: 152-9.
25Spick C, Bickel H, Polanec SH, Baltzer PA. Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis. Eur Radiol 2018; 28: 1919-28.
26Giess CS, Yeh ED, Raza S, Birdwell RL. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation. Radiographics 2014; 34: 234-47.
27Yang QX, Ji X, Feng LL, Zheng L, Zhou XQ, Wu Q, et al. Significant MRI indicators of malignancy for breast non-mass enhancement. J Xray Sci Technol 2017; 25: 1033-44.
28Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292: 2735-42.
29Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Giger M, et al. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement? Med Phys 2008; 35: 3102-9.
30Mori N, Sheth D, Abe H. Nonmass enhancement breast lesions: diagnostic performance of kinetic assessment on ultrafast and standard dynamic contrast-enhanced MRI in comparison with morphologic evaluation. AJR Am J Roentgenol 2020; 215: 511-8.
31Baltzer PA, Dietzel M, Kaiser WA. Nonmass lesions in magnetic resonance imaging of the breast: additional T2-weighted images improve diagnostic accuracy. J Comput Assist Tomogr 2011; 35: 361-6.
32Uematsu T. Focal breast edema associated with malignancy on T2-weighted images of breast MRI: peritumoral edema, prepectoral edema, and subcutaneous edema. Breast Cancer 2015; 22: 66-70.
33Bickelhaupt S, Laun FB, Tesdorff J, Lederer W, Daniel H, Stieber A, et al. Fast and Noninvasive Characterization of Suspicious Lesions Detected at Breast Cancer X-ray screening: capability of diffusion-weighted MR imaging with MIPs. Radiology 2016; 278: 689-97.
34Avendano D, Marino MA, Leithner D, Thakur S, Bernard-Davila B, Martinez DF, et al. Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI. Breast Cancer Res 2019; 21: 136.
35Bickel H, Pinker K, Polanec S, Magometschnigg H, Wengert G, Spick C, et al. Diffusion-weighted imaging of breast lesions: Region-of-interest placement and different ADC parameters influence apparent diffusion coefficient values. Eur Radiol 2017; 27: 1883-92.
36Pinker K, Chin J, Melsaether AN, Morris EA, Moy L. Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. Radiology 2018; 287: 732-47.
37Li Y, Yang ZL, Lv WZ, Qin YJ, Tang CL, Yan X, et al. Non-mass enhancements on DCE-MRI: development and validation of a radiomics-based signature for breast cancer diagnoses. Front Oncol 2021; 11: 738330.
38Tan Y, Mai H, Huang Z, Zhang L, Li C, Wu S, et al. Additive value of texture analysis based on breast MRI for distinguishing between benign and malignant non-mass enhancement in premenopausal women. BMC Med Imaging 2021; 21: 48.